HU-211/ DEXANABINOL/ ETS-2101 – synthetic, CB 2 agonist

 

A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat.                                               (abst – 1993)       http://www.ncbi.nlm.nih.gov/pubmed/8411215

 

HU-211, a Novel Noncompetitive N-Methyl-D-Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat           (full – 1995)                                                    http://stroke.ahajournals.org/cgi/content/full/26/12/2313

 

45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211.                                                                    (abst – 1995)    http://www.ncbi.nlm.nih.gov/pubmed/7583233

 

Development of HU-211 as a neuroprotectant for ischemic brain damage.                   (abst – 1995)

http://www.ncbi.nlm.nih.gov/pubmed/7477742

 

A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis.        (full – 1996)                                                  http://jid.oxfordjournals.org/content/173/3/735.long

 

HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy.                                                               (abst – 1996)        http://www.ncbi.nlm.nih.gov/pubmed/8714863

 

Protection Against Septic Shock and Suppression of Tumor Necrosis Factor α and Nitric Oxide Production by Dexanabinol (HU-211), a Nonpsychotropic Cannabinoid

(full – 1997)                       http://jpet.aspetjournals.org/content/283/2/918.full

 

Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant.                                                  (abst – 1997)  http://www.ncbi.nlm.nih.gov/pubmed/9042110

 

Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. (abst – 1999)                                          http://www.ncbi.nlm.nih.gov/pubmed/10202976

 

Cannabinoids in clinical practice.                     (abst – 2000)

http://www.ncbi.nlm.nih.gov/pubmed/11152013

 

Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.                                                                    (abst – 2002)  http://www.ncbi.nlm.nih.gov/pubmed/11990913?dopt=Abstract

 

Dexanabinol: a novel cannabinoid with neuroprotective properties.                      (abst – 2003)

http://www.ncbi.nlm.nih.gov/pubmed/14534855

 

 

 

 

 

 

 

 

Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury.                                                             (abst – 2003)        http://www.ncbi.nlm.nih.gov/pubmed/12535983

 

Therapeutic potential of cannabinoids in CNS disease.                    (abst – 2003)

http://www.ncbi.nlm.nih.gov/pubmed/12617697

 

Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol. (abst – 2003)                                          http://www.ncbi.nlm.nih.gov/pubmed/12757406

 

Dexanabinol prevents development of vasospasm in the rat femoral artery model. (abst – 2008)                                          http://www.ncbi.nlm.nih.gov/pubmed/18256864

 

Latest Studies Imply That Cannabinoids Are Protective Against Alcohol-Induced Brain Damage            (news – 2011)                         http://networkedblogs.com/mFuuX

 

Cannabinoid May Treat Brain Cancer                      (news – 2012)

http://www.sciencedaily.com/releases/2012/09/120925142557.htm?utm_source=feedburner&utm_medium

=feed&utm_campaign=Feed%3A+sciencedaily+%28ScienceDaily%3A+Latest+Science+News%29

 

Clinical trial evaluates synthetic cannabinoid as brain cancer treatment                       (news – 2012)

http://medicalxpress.com/news/2012-09-clinical-trial-synthetic-cannabinoid-brain.html

Share a link for